<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465088</url>
  </required_header>
  <id_info>
    <org_study_id>019-05-06-CR</org_study_id>
    <secondary_id>M10-013</secondary_id>
    <nct_id>NCT00465088</nct_id>
  </id_info>
  <brief_title>An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)</brief_title>
  <acronym>SUPREME</acronym>
  <official_title>SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin
      (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating
      effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are
      currently off lipid-modifying therapy. This was a prospective, randomized, open-label,
      blinded endpoint (PROBE) study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in HDL-C From Baseline to Week 8</measure>
    <time_frame>From baseline to Week 8</time_frame>
    <description>(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C From Baseline to Week 8</measure>
    <time_frame>From baseline to Week 8</time_frame>
    <description>(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-HDL-C From Baseline to Week 12</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline to Week 12</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C:HDL-C Ratio</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol From Baseline to Week 12</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol:HDL-C Ratio</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Lipoprotein A From Baseline to Week 12</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Meeting With HDL-C &gt;/= 40 mg/dL at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>For high-risk patients (coronary heart disease or equivalent), LDL-C &lt; 100 mg/dL and non-HDL-C &lt; 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C &lt; 130 mg/dL and non-HDL-C &lt; 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C &lt; 160 mg/dL and non-HDL-C &lt; 190 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Triglycerides &lt; 150 mg/dL at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With HDL-C &gt;/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides &lt; 150 mg/dL at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C &lt; 100 mg/dL; for moderate risk patients, LDL-C &lt; 130 mg/dL; for low-risk patients: LDL-C &lt; 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin ER/Simvastatin Tablets</intervention_name>
    <description>Up to 2000 mg/40 mg at bedtime</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ABT-919/483</other_name>
    <other_name>Niacin ER/Simvastatin</other_name>
    <other_name>Simcor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>40 mg at bedtime</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must meet all of the following laboratory criteria:

               -  HDL-C &lt;40 mg/dL for men and &lt;50 mg/dL for women.

               -  LDL-C ≥130 mg/dL but &lt;250 mg/dL.

               -  TG &lt;350 mg/dL.

               -  Creatine phosphokinase (CPK) &lt; 3 x upper limit of normal (ULN).

               -  Alanine aminotransferase (ALT); serum glutamic pyruvic transaminase [SGPT] and
                  aspartate aminotransferase (AST); serum glutamic oxaloacetic transaminase [SGOT]
                  &lt; 1.3 x ULN.

          -  Subjects must also be reasonably compliant with the Therapeutic Lifestyle Changes
             (TLC) diet during the 4 to 5 week Screening Period prior to randomization (and be
             willing to comply for the duration of the study).

        Exclusion Criteria:

          -  Subjects who have a history of any important medical conditions or abnormalities (as
             specified in the protocol) that would preclude study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roopal Thakkar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32953</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calhoun</city>
        <state>Georgia</state>
        <zip>30701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>55508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canfield</city>
        <state>Ohio</state>
        <zip>44406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Protland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicora</city>
        <state>Pennsylvania</state>
        <zip>16025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <zip>19438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magna</city>
        <state>Utah</state>
        <zip>84044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gig Harbor</city>
        <state>Washington</state>
        <zip>98335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2007</study_first_submitted>
  <study_first_submitted_qc>April 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <results_first_submitted>February 10, 2009</results_first_submitted>
  <results_first_submitted_qc>March 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2009</results_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Scott Krause, AD Clinical Research</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 199 subjects randomized, 6 did not receive study drug: 2 withdrew consent, 1 had a protocol violation, and 3 had randomization errors. 193 subjects were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Niacin Extended-release Plus Simvastatin</title>
          <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin</title>
          <description>40 mg atorvastatin once daily at bedtime</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114">For both arms, started means treated.</participants>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Niacin Extended-release Plus Simvastatin</title>
          <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin</title>
          <description>40 mg atorvastatin once daily at bedtime</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="193"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="12.06"/>
                    <measurement group_id="B2" value="51.5" spread="11.12"/>
                    <measurement group_id="B3" value="53.6" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12</title>
        <description>(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12</title>
          <description>(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C</description>
          <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="25.6" upper_limit="34.6"/>
                    <measurement group_id="O2" value="9.4" lower_limit="4.3" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An n = 81 for niacin extended-release with simvastatin and n = 54 for atorvastatin would provide &gt; 99% power to detect a 13% increase in HDL-C with niacin extended-release with simvastatin relative to atorvastatin, assuming an SD of 16%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>alpha = 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in HDL-C From Baseline to Week 8</title>
        <description>(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C</description>
        <time_frame>From baseline to Week 8</time_frame>
        <population>All treated subjects whose Week 8 value was obtained within the Week 8 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in HDL-C From Baseline to Week 8</title>
          <description>(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C</description>
          <population>All treated subjects whose Week 8 value was obtained within the Week 8 visit window</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="23.1" upper_limit="30.2"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-2.7" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C From Baseline to Week 8</title>
        <description>(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C</description>
        <time_frame>From baseline to Week 8</time_frame>
        <population>All treated subjects whose Week 8 value was obtained within the Week 8 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C From Baseline to Week 8</title>
          <description>(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C</description>
          <population>All treated subjects whose Week 8 value was obtained within the Week 8 visit window</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.0" lower_limit="-48.9" upper_limit="-41.0"/>
                    <measurement group_id="O2" value="-44.3" lower_limit="-48.8" upper_limit="-39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Non-HDL-C From Baseline to Week 12</title>
        <description>(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Non-HDL-C From Baseline to Week 12</title>
          <description>(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C</description>
          <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.4" lower_limit="-47.7" upper_limit="-39.0"/>
                    <measurement group_id="O2" value="-43.3" lower_limit="-48.2" upper_limit="-38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12</title>
        <description>(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window (between 70 days after first dose and not more than 3 days after last dose)</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12</title>
          <description>(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C</description>
          <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window (between 70 days after first dose and not more than 3 days after last dose)</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.8" lower_limit="-48.3" upper_limit="-39.2"/>
                    <measurement group_id="O2" value="-46.0" lower_limit="-51.0" upper_limit="-40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline to Week 12</title>
        <description>(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline to Week 12</title>
          <description>(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides</description>
          <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.0" lower_limit="-62.8" upper_limit="-20.9"/>
                    <measurement group_id="O2" value="-37.0" lower_limit="-47.8" upper_limit="-18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C:HDL-C Ratio</title>
        <description>(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 values were obtained within the Week 12 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C:HDL-C Ratio</title>
          <description>(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio</description>
          <population>All treated subjects whose Week 12 values were obtained within the Week 12 visit window</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.5" lower_limit="-59.1" upper_limit="-49.8"/>
                    <measurement group_id="O2" value="-50.5" lower_limit="-55.7" upper_limit="-45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol From Baseline to Week 12</title>
        <description>(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol From Baseline to Week 12</title>
          <description>(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol</description>
          <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.3" lower_limit="-34.8" upper_limit="-27.7"/>
                    <measurement group_id="O2" value="-35.1" lower_limit="-39.1" upper_limit="-31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol:HDL-C Ratio</title>
        <description>(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 values were obtained within the Week 12 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol:HDL-C Ratio</title>
          <description>(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio</description>
          <population>All treated subjects whose Week 12 values were obtained within the Week 12 visit window</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.2" lower_limit="-49.0" upper_limit="-41.3"/>
                    <measurement group_id="O2" value="-40.3" lower_limit="-44.7" upper_limit="-36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Lipoprotein A From Baseline to Week 12</title>
        <description>(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Lipoprotein A From Baseline to Week 12</title>
          <description>(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A</description>
          <population>All treated subjects whose Week 12 value was obtained within the Week 12 visit window</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" lower_limit="-36.8" upper_limit="8.8"/>
                    <measurement group_id="O2" value="16.0" lower_limit="-7.1" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Meeting With HDL-C &gt;/= 40 mg/dL at Week 12</title>
        <time_frame>12 weeks</time_frame>
        <population>All treated subjects not meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III goals at baseline with both a baseline and at least 1 postbaseline HDL-C value</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Meeting With HDL-C &gt;/= 40 mg/dL at Week 12</title>
          <population>All treated subjects not meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III goals at baseline with both a baseline and at least 1 postbaseline HDL-C value</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12</title>
        <description>For high-risk patients (coronary heart disease or equivalent), LDL-C &lt; 100 mg/dL and non-HDL-C &lt; 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C &lt; 130 mg/dL and non-HDL-C &lt; 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C &lt; 160 mg/dL and non-HDL-C &lt; 190 mg/dL.</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated subjects not meeting NCEP ATP III goals at baseline with both a baseline and at least 1 postbaseline LDL-C value</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12</title>
          <description>For high-risk patients (coronary heart disease or equivalent), LDL-C &lt; 100 mg/dL and non-HDL-C &lt; 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C &lt; 130 mg/dL and non-HDL-C &lt; 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C &lt; 160 mg/dL and non-HDL-C &lt; 190 mg/dL.</description>
          <population>All treated subjects not meeting NCEP ATP III goals at baseline with both a baseline and at least 1 postbaseline LDL-C value</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Triglycerides &lt; 150 mg/dL at Week 12</title>
        <time_frame>12 weeks</time_frame>
        <population>All treated subjects not meeting NCEP ATP III goals at baseline with both a baseline and at least 1 postbaseline triglyceride value</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Triglycerides &lt; 150 mg/dL at Week 12</title>
          <population>All treated subjects not meeting NCEP ATP III goals at baseline with both a baseline and at least 1 postbaseline triglyceride value</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With HDL-C &gt;/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides &lt; 150 mg/dL at Week 12</title>
        <description>NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C &lt; 100 mg/dL; for moderate risk patients, LDL-C &lt; 130 mg/dL; for low-risk patients: LDL-C &lt; 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated subjects not meeting NCEP ATP III goals at baseline with both a baseline and at least 1 postbaseline value for all 3 lipid parameters</population>
        <group_list>
          <group group_id="O1">
            <title>Niacin Extended-release Plus Simvastatin</title>
            <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>40 mg atorvastatin once daily at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With HDL-C &gt;/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides &lt; 150 mg/dL at Week 12</title>
          <description>NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C &lt; 100 mg/dL; for moderate risk patients, LDL-C &lt; 130 mg/dL; for low-risk patients: LDL-C &lt; 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor.</description>
          <population>All treated subjects not meeting NCEP ATP III goals at baseline with both a baseline and at least 1 postbaseline value for all 3 lipid parameters</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Niacin Extended-release Plus Simvastatin</title>
          <description>Up to 2000 mg of niacin extended-release plus 40 mg simvastatin once daily at bedtime</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin</title>
          <description>40 mg atorvastatin once daily at bedtime</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.0</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89"/>
                <counts group_id="E2" subjects_affected="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to release; Sponsor shall receive up to 180 days for review. Differences shall be resolved in good faith through appropriate scientific debate.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

